Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4873717
Max Phase: Preclinical
Molecular Formula: C29H24F4N4O3
Molecular Weight: 552.53
Molecule Type: Unknown
Associated Items:
ID: ALA4873717
Max Phase: Preclinical
Molecular Formula: C29H24F4N4O3
Molecular Weight: 552.53
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCN1C(=O)[C@@H](NC(=O)c2cccc(C(F)(F)F)c2)[C@@H](c2ccc(F)cc2)c2c(CO)nn(-c3ccccc3)c21
Standard InChI: InChI=1S/C29H24F4N4O3/c1-2-36-27-24(22(16-38)35-37(27)21-9-4-3-5-10-21)23(17-11-13-20(30)14-12-17)25(28(36)40)34-26(39)18-7-6-8-19(15-18)29(31,32)33/h3-15,23,25,38H,2,16H2,1H3,(H,34,39)/t23-,25-/m0/s1
Standard InChI Key: UXJOOGBBJOXRET-ZCYQVOJMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 552.53 | Molecular Weight (Monoisotopic): 552.1785 | AlogP: 4.82 | #Rotatable Bonds: 6 |
Polar Surface Area: 87.46 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.31 | CX Basic pKa: 0.44 | CX LogP: 4.44 | CX LogD: 4.44 |
Aromatic Rings: 4 | Heavy Atoms: 40 | QED Weighted: 0.34 | Np Likeness Score: -1.15 |
1. Kim HS, Hammill JT, Scott DC, Chen Y, Rice AL, Pistel W, Singh B, Schulman BA, Guy RK.. (2021) Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M., 64 (9.0): [PMID:33945681] [10.1021/acs.jmedchem.1c00035] |
Source(1):